CAFs promote VM in HCC via TGF-β/SDF1-induced VE-cadherin/MMP2/LAMC2 axis, while miR-101 can suppress VM by dual targeting TGF-βR1/Smad2 in HCC cells and SDF1 in CAFs for anti-metastasis therapy (48). This evidence concerns the gene SMAD2 and hepatocellular carcinoma.